TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A Michigan physician was convicted of distributing more than 2 million stimulant pills through the Done ADHD telehealth platform, according to the Justice Department. Separately, the FDA cleared Click Therapeutics’ Motivista as an adjunctive digital treatment for negative symptoms of schizophrenia in outpatient care. The report also notes rising discussion of AI-related anxiety in therapy, but gives no data on how common it is.
A Michigan physician was convicted of peddling more than 2 million stimulant pills, including Adderall, through the Done ADHD telehealth platform, the U.S. Department of Justice said, while the FDA separately cleared Motivista as an adjunctive digital treatment for negative symptoms of schizophrenia. The two developments, reported in a psychiatry news roundup published October 7, 2026, involve separate questions of controlled-drug oversight and digital mental-health care.
The Justice Department identified the physician as Jonathan Decker, MD, of Michigan. It said the conviction concerned more than 2 million stimulant pills, including amphetamine-dextroamphetamine salts sold under the brand name Adderall, distributed through the Done ADHD telehealth platform. The source report does not state the charges, verdict date, sentence, or whether Decker plans to appeal.
In a separate development, the FDA cleared Motivista, a prescription digital therapeutic developed by Click Therapeutics, as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. Click Therapeutics announced the clearance, according to the report. “Adjunctive” means the product is intended to be used alongside other care, rather than described in the source as a replacement for established treatment.
The roundup also noted that anxiety about artificial intelligence is becoming a topic in therapy sessions, citing The New York Times. It provided no survey figures, clinical findings, or details about how therapists are responding. Other items in the roundup included federal interest in public input on ibogaine research and a Senate vote on mental-health support for airline professionals; those developments are distinct from the conviction and FDA clearance.
Oversight and Digital Mental Health
The conviction highlights the legal and public-health stakes of prescribing controlled stimulants through telehealth. The number cited by the Justice Department is substantial, but the available report does not explain how the pills were prescribed, dispensed, or counted, or describe the evidence presented at trial. The conviction concerns Decker; it does not, on the information provided, establish wrongdoing by the platform or other clinicians.
Motivista’s FDA clearance adds a regulated digital option to care for people with schizophrenia, specifically targeting negative symptoms and intended for outpatient use as an adjunct. The development may be relevant to patients and clinicians considering technology-supported care, but the source does not provide trial results, eligibility criteria, treatment duration, or information on availability and cost. Clearance should not be read as evidence that the product replaces medication or other clinical support.
The AI-anxiety item points to a changing subject in mental-health conversations, but it is a reported observation rather than a quantified trend in this source. Readers cannot infer how many people experience such anxiety or whether it is increasing based on the brief mention alone.
Products Worth Considering
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Therabody JetBoots Prime Wireless Compression Boots – Short (under 29 inseam)
Therabody Theragun Prime 6th Generation Deep Tissue Massage Gun, Navy
As an affiliate, we earn on qualifying purchases.
Three Developments in Psychiatry
The source is a short MedPage Today psychiatry roundup dated October 7, 2026, not a single investigation covering all the items. It combines a Justice Department account of a criminal conviction, a company announcement about an FDA decision, and references to other reporting and research. Those items have different evidentiary bases and should be read separately.
The roundup describes Motivista as a prescription digital therapeutic cleared for use alongside other care in outpatient settings. It does not give the FDA’s decision documents or explain the precise regulatory pathway. Similarly, the pill case is summarized through the Justice Department’s account, without court records or a detailed account of the prosecution. The AI-anxiety item is attributed to The New York Times, rather than supported in the roundup by new clinical data.
“The FDA cleared the prescription digital therapeutic Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care.”
— Click Therapeutics, as summarized by MedPage Today
Missing Case and Product Details
The available report does not identify the specific conviction date, charges, trial evidence, or sentence in Decker’s case. It also does not say whether an appeal is planned, or describe any legal action involving Done ADHD. Those points cannot be established from the supplied material.
For Motivista, the report does not provide clinical-trial outcomes, safety information, patient eligibility, prescribing instructions, launch timing, or cost. The exact scope and conditions of the FDA clearance are not detailed beyond its adjunctive use for negative symptoms in outpatient care. The AI-anxiety reference likewise contains no figures or explanation of whether the observation comes from clinicians, patients, or research.
Court and Care Details to Follow
Further information about the conviction would clarify the charges, sentence, court’s findings, and any appeal. The Justice Department’s account is the only case detail provided in the source material; no timetable for additional proceedings is specified.
For Motivista, clinicians and patients will need product-specific information about who may use it, how it fits with existing care, and when it will be available. The roundup does not provide a launch date or say whether Click Therapeutics has announced one. More reporting or published research would also be needed to put claims about AI-related anxiety in therapy sessions into measurable context.
Key Questions
Who was convicted in the stimulant-pill case?
The Justice Department identified the doctor as Jonathan Decker, MD, of Michigan. The roundup says he was convicted in a case involving more than 2 million stimulant pills distributed through the Done ADHD telehealth platform.
What is Motivista cleared to treat?
According to the report, the FDA cleared Motivista as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. The source does not provide the full clearance documents or patient-use instructions.
Does the report say Motivista replaces other schizophrenia care?
No. It describes Motivista as adjunctive, meaning it is intended to accompany other care. The report does not state that it replaces medication, therapy, or clinician support.
What is known about AI-related anxiety in therapy?
The roundup says anxiety about AI is becoming a topic in therapy sessions, citing The New York Times. It provides no prevalence figures or clinical study findings, so the scale of the issue remains unclear.
Source: rss
